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stem features.5,6 Only one of the very 
few GFP-positive keratinocyte colonies 
derived from cells recovered from the 
cell-sorting procedure maintained an 
undifferentiated phenotype and grew 
larger than two centimeters in diameter, 
consistent with the characteristics of an 
epidermal stem cell derivative or holo-
clone.7,8 The rest of the colonies grew no 
larger than 2–3 mm in diameter after 
15 days in culture (data not shown). 
Nonviable, differentiating keratinocyte 
colonies were scraped out from the flask, 
and the large colony was harvested and 
cells expanded to perform EGFP fluores-
cence and DNA analysis, and grafting. 
Detailed materials and methods are 
given in the Supplementary Materials 
and Methods online).
In contrast to a polyclonal EGFP-
expressing keratinocyte population after 
standard retroviral transduction, the 
expanded clone displayed, under the 
microscope, a homogeneous morphol-
ogy and fluorescence (Figure 1a,b and 
Supplementary Figure S1b,c) and a 
sharp peak of fluorescence, detected by 
flow cytometry, indicative of uniform 
EGFP expression (Figure 1c). PCR 
analysis of DNA isolated from the clone 
showed amplified DNA bands consistent 
with “on target” integration of the PGK-
EGFP, HR-cassette in the AAVS1 locus 
(Figure 1d).4 Southern blot analysis 
confirmed targeted integration and the 
absence of additional “off target” HR 
cassette integrations (Supplementary 
Figure S2a,b). Cytogenetic analysis 
revealed a normal (46,XY) karyotype 
with no detectable structural chro-
mosomal abnormalities (Figure 1e). 
Bioengineered skin equivalents prepared 
with the expanded-clone keratinocytes 
were grafted to immunodeficient mice. 
Four weeks after grafting, human skin 
regeneration was confirmed by detection 
of EGFP epifluorescence in five out of 
six transplanted mice.
Twelve weeks after grafting, when 
approximately three epidermal turnover 
cycles should have occurred, macroscopic 
inspection was performed (Figure 2a,b) 
and skin biopsy samples taken from en-
grafted skin for histological examination 
and for PCR analysis to confirm AAVS1 
locus–targeted transgene integration. 
The analysis revealed regeneration of a 
normal, EGFP-fluorescent human skin 
(Figure 2c) with typical histological 
architecture and proper expression of dif-
ferentiation markers (Figure 2d and Sup-
plementary Figure S3). The molecular 
analysis showed that the grafts rendered 
the correct transgene integration PCR 
amplicons, exactly as the cells in culture, 
ruling out selection of putative off-target 
or gene rearrangement events in vivo 
(Supplementary Figure S2c). Overall, we 
could demonstrate the feasibility of se-
lecting gene-targeted epidermal cells with 
long-term repopulating ability consistent 
with stem cell features.
Therapeutic approaches such as HR 
using primary human keratinocytes 
require individual clonal analysis not 
only to characterize the gene-targeting 
event but also to assess the regenerative 
capacity of individual clone(s) using 
stringent in vivo assays. Recently Melo 
et al. reported LAMA3 correction in 
JEB human keratinocytes through 
AAV-mediated HR.9 However, in their 
short-term (5 weeks after grafting) in 
vivo assessment of skin regeneration 
conducted with pools of keratinocytes, 
targeting of bona fide epidermal stem 
cells required for permanent gene cor-
rection could not be confirmed. Our 
previous long-term in vivo study show-
ing the persistence of small (AAVS1-
targeted), EGFP-positive skin foci 
suggested the epidermal stem cell nature 
of the cells originating them.4 However, 
because these foci comprised <1% of the 
total graft surface, the definitive compe-
tence for whole epidermal regeneration, 
needing robust proliferative capacity 
of targeted cell clones, had not been 
strictly proven. We used an optimized 
in vivo approach, previously employed 
to establish humanized skin models and 
therapeutic options for several genoder-
matoses10–12 and to assess the safety and 
regenerative capacity of isolated holo-
clones genetically modified with retro-
viral vectors.13 Here this system allowed 
us to demonstrate that epidermal stem 
cells subjected to transient expression of 
DNA nucleases preserve their epidermal 
repopulating competence in vivo.
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Ex vivo gene therapy is one of the 
current strategies being tested to treat 
genodermatoses such as epidermoly-
sis bullosa (EB).1 In fact, Mavilio et al. 
proved the feasibility of this therapeutic 
modality in a patient with the junctional 
form of EB (JEB).2 Efforts are now being 
directed toward the development of ef-
ficient approaches minimizing potential 
genotoxic effects due to vector-induced 
insertional mutagenesis. Gene correc-
tion by gene editing through nuclease-
facilitated homologous recombination 
(HR) has recently been proven to be 
achievable on recessive dystrophic 
EB cells that were subsequently re-
programmed to induced pluripotent 
stem cells (iPSCs) and differentiated to 
collagen VII–expressing keratinocytes.3 
We have also demonstrated the feasibil-
ity of zinc-finger nuclease–facilitated, 
HR-mediated insertion of a marker gene 
into the intron 1 of the PPP1R12C gene 
(AAVS1 locus) in a limited number of 
human epidermal repopulating cells 
that, upon grafting, persisted as small 
foci in skin regenerated in immunodefi-
cient mice.4 In this study we report that 
engraftment and persistent skin regener-
ation can be achieved with an expanded 
stem cell clone isolated from AAVS1 
gene–targeted human keratinocytes.
We first determined whether sorted 
enhanced green fluorescent protein 
(EGFP)-positive cells, present in low 
proportion (<0.1%) of the HR-targeted 
human keratinocytes (ref. 4 and Supple-
mentary Figure S1a online), could be 
isolated and expanded in culture. Our 
previous attempts at growing EGFP-
positive, FACS-selected cells from a bulk 
population containing <5% of EGFP-
positive human keratinocytes had failed. 
To overcome this limitation, we supple-
mented our culture medium with the 
ROCK inhibitor Y-27632 to enhance the 
expansion of sorted keratinocytes with 
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Moreover, we can confirm that a 
strategy based on skin regeneration from 
single or a limited number of gene-cor-
rected clones is realistic. However, given 
the targeting efficiencies achieved with 
current gene-editing tools, robust meth-
ods of cell selection are still required. 
This could be achieved by using either 
a Cre/loxP removable selection cassette 
or a constitutive marker compatible with 
clinical applications.
With the advent of novel gene-
editing techniques and other strategies, 
such as the derivation of true corrected 
human epidermal stem cells from iPSCs 
capable of permanent skin regeneration, 
clonal analyses assessing their efficacy 
are likely to be required. Our study 
paves the way for the development of 
such future clonal correction-based 
therapeutic approaches.
SUPPLEMENTARY MATERIAL
Supplementary Materials and Methods
Supplementary Figure S1. Morphologi-
cal and fluorescence features of AAVS1-
targeted holoclone cells.
Supplementary Figure S2. Molecular 
analyses of AAVS1-targeted holoclone cells 
and derived grafts.
Supplementary Figure S3. Expression of 
epidermal differentiation markers in AAVS1-
targeted holoclone grafts.
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Figure 1 Morphological, molecular, and cytogenetic characteristics of AAVS1 gene–
targeted keratinocyte clone. (a) Microscopic appearance (phase contrast) of the clone grown 
in the presence of lethally irradiated feeder layer cells. (b) Green fluorescent protein (GFP) fluo-
rescence corresponding to the cells shown in a. (c) Flow cytometry fluorescence analysis of clone 
cells showing a sharp peak of fluorescence indicative of uniform GFP expression. (d) PCR analysis 
of transgene cassette integration (TI) within the AAVS1 intron 1 locus. The 1.3-kbp and 0.9-kbp 
bands (arrows) demonstrate targeted integration of the cassette at 3ʹ and 5ʹ genome junctions, 
respectively. Lane –, mock PCR amplification; lane C+, PCR amplification of DNA from a positive 
control; lane C–, PCR amplification from normal human DNA; lane KC, PCR amplification of DNA 
from AAVS1-targeted keratinocyte clone. (e) Cytogenetic analysis of the clonal, gene-targeted 
keratinocytes. The GTG banding shows a normal 46,XY karyotype.
Figure 2 Macroscopic and microscopic appearance of the human skin regenerated 
from clonal gene-targeted keratinocytes. (a) A representative engrafted mouse showing 
human regenerated skin (dotted square) 12 weeks after grafting of bioengineered skin carrying 
AAVS1 locus–targeted clonal keratinocytes. (b) Macroscopic appearance (with illumination) of 
the regenerated skin shown depicted by the dotted square in the engrafted mouse of panel a. 
(c) Enhanced green fluorescent protein (EGFP) epifluorescence (blue-light illumination) of the 
engrafted skin shown in panel b. (d) Microphotograph (H&E-stained) of a skin section from a 
12-week-old graft showing normal human skin architecture. The inset (right upper) shows the 
normal expression of involucrin using a human-specific monoclonal antibody to involucrin. (e) 
EGFP fluorescence detection in a frozen section (paraformaldehyde-fixed) from the graft analyzed 
in panel d. DAPI staining shows nuclei. The inset shows the direct EGFP fluorescence observed via 
fluorescence phase-contrast microscopy. DAPI, 4’,6-diamidino-2-phenylindole.
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